MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation
Clinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3, monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovascular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death). Patients with persistent inflammation (n = 343) showed higher NT-proBNP and MCP-1 plasma levels compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels were associated with increased risk of the primary outcome in patients with persistent inflammation. When patients were divided by type of event, MCP-1 was associated with an increased risk of acute ischemic events. A significant interaction between MCP-1 and persistent inflammation was found (synergy index: 6.17 (4.39-7.95)). In conclusion, MCP-1 plasma concentration is associated with recurrent cardiovascular events in patients with persistent inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 10(2021), 5 vom: 09. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Blanco-Colio, Luis M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.04.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm10051137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323586031 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323586031 | ||
| 003 | DE-627 | ||
| 005 | 20231225184510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10051137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323586031 | ||
| 035 | |a (NLM)33803115 | ||
| 035 | |a (PII)1137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Blanco-Colio, Luis M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Clinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3, monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovascular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death). Patients with persistent inflammation (n = 343) showed higher NT-proBNP and MCP-1 plasma levels compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels were associated with increased risk of the primary outcome in patients with persistent inflammation. When patients were divided by type of event, MCP-1 was associated with an increased risk of acute ischemic events. A significant interaction between MCP-1 and persistent inflammation was found (synergy index: 6.17 (4.39-7.95)). In conclusion, MCP-1 plasma concentration is associated with recurrent cardiovascular events in patients with persistent inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a MCP-1 | |
| 650 | 4 | |a NT-proBNP | |
| 650 | 4 | |a inflammation | |
| 700 | 1 | |a Méndez-Barbero, Nerea |e verfasserin |4 aut | |
| 700 | 1 | |a Pello Lázaro, Ana María |e verfasserin |4 aut | |
| 700 | 1 | |a Aceña, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Tarín, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a Cristóbal, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Milla, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a González-Lorenzo, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Ventura, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Huelmos, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Landaluce, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a López-Castillo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Kallmeyer, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cánovas, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a López Bescós, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Egido, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Tuñón, José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 5 vom: 09. März |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:5 |g day:09 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10051137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 5 |b 09 |c 03 | ||